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Background: Various types of framing can influence risk perceptions, which may have an impact on treatment
decisions and adherence. One way of framing is the use of verbal terms in communicating the probabilities of
treatment effects. We systematically reviewed the comparative effects of words versus numbers in communicating
the probability of adverse effects to consumers in written health information.
Methods: Nine electronic databases were searched up to November 2012. Teams of two reviewers independently
assessed studies. Inclusion criteria: randomised controlled trials; verbal versus numerical presentation; context:
written consumer health information.
Results: Ten trials were included. Participants perceived probabilities presented in verbal terms as higher than in
numeric terms: commonly used verbal descriptors systematically led to an overestimation of the absolute risk of
adverse effects (Range of means: 3% - 54%). Numbers also led to an overestimation of probabilities, but the
overestimation was smaller (2% – 20%). The difference in means ranged from 3.8% to 45.9%, with all but one
comparison showing significant results. Use of numbers increased satisfaction with the information (MD: 0.48 [CI:
0.32 to 0.63], p < 0.00001, I2 = 0%) and likelihood of medication use (MD for very common side effects: 1.45 [CI: 0.78
to 2.11], p = 0.0001, I2 = 68%; MD for common side effects: 0.90 [CI: 0.61 to 1.19], p < 0.00001, I2 = 1%; MD for rare
side effects: 0.39 [0.02 to 0.76], p = 0.04, I2 = not applicable). Outcomes were measured on a 6-point Likert scale,
suggesting small to moderate effects.
Conclusions: Verbal descriptors including “common”, “uncommon” and “rare” lead to an overestimation of the
probability of adverse effects compared to numerical information, if used as previously suggested by the European
Commission. Numbers result in more accurate estimates and increase satisfaction and likelihood of medication use.
Our review suggests that providers of consumer health information should quantify treatment effects numerically.
Future research should focus on the impact of personal and contextual factors, use representative samples or be
conducted in real life settings, measure behavioral outcomes and address whether benefit information can be
described verbally.
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Ideally, patient decisions for and against medical treat-
ments are made in the presence of knowledge of the best
available evidence for the benefits and harms of these
treatments. Personal preferences and values can influence
treatment decisions and may – legitimately – lead people
to make choices which are not necessarily in line with the
evidence. There are, however, some cognitive biases that
may interfere with treatment. In particular, various types
of data framing can influence risk perceptions [1].
Poorly framed information on the risk of adverse ef-
fects of drugs or other medical interventions may cause
misinterpretation of the risks of harms. This may have
an impact on treatment decisions and might also affect
medication adherence. The 1995 contraceptive pill
scare in the UK highlights the importance of helping
doctors and patients understand risk information:
media reports and “Dear Doctor” letters reported that
the third-generation contraceptive pills increased the
(relative) risk of blood clots by 100%, which caused
many women to stop taking the pill and led to many
unwanted pregnancies and abortions – although the
absolute risk increase was as small as 0.014% [2].
One way of framing information is the use of words in
communicating the probabilities of treatment effects.
A prominent example for a nomenclature of words
used to communicate frequencies of adverse effects is
the one proposed by the European Commission in
their 1998 guidelines on the readability of package leaf-
lets and summary of product characteristics from the
European Medical Association [3,4]. Table 1 shows the
wording suggested in these guidelines.
Several studies have compared the use of verbal terms
versus numbers for communicating the frequency of
adverse drug effects. However, to our knowledge no
systematic review on the comparative effects of verbal
versus numerical presentations of the frequency of ad-
verse effects has been conducted. Risk communication
has become a vast field which is difficult to keep up
with. Thus, current recommendations on risk commu-
nication are often based on expert consensus or a se-
lective review of the literature. For example, both the
International Patient Decision Aid Standards (IPDAS)Table 1 European commission nomenclature for
communicating frequency of adverse effects of drugs
Description Frequency interval
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1000 to <1/100)
Rare (≥1/10000 to <1/1000)
Very rare (<1/10000)
Not known cannot be estimated from the available dataand the FDA’s user’s guide on communicating risks and
benefits currently do not cite many of the studies we
identified in our preliminary searches. The aim of this
systematic review is to improve the evidence base of
risk communication strategies by gathering and synthesiz-




We included studies examining the effects of words ver-
sus numbers in communicating harms of treatments to
consumers in written health information. Our inclusion
criteria were: (1) study design: randomized controlled
trials (RCTs); (2) outcomes: interpretation of probabil-
ity, comprehension, recall, satisfaction, impact on deci-
sion, likelihood of treatment utilization, adherence and
psychological outcomes (e.g. anxiety); (3) context: treat-
ment effects were communicated through written health
information only and (4) language: studies published in
English or German.
Data sources and search methods
We searched MEDLINE, Embase, PsycINFO, CINAHL,
ERIC, DARE, the CDSR, CENTRAL and the Campbell
Library. Searches were developed and conducted by an
information specialist using a combination of MeSH-
terms, free text and validated search filters for specific
study designs, where available. See Additional file 1 for
the search strategy used to identify relevant studies in
MEDLINE. This was adapted as required to other
databases. Searches were conducted up to the 9th of
November 2012. Titles and abstract of search results
were assessed for eligibility independently by three re-
viewers in pairs. Full texts of potentially relevant studies
were retrieved and assessed for eligibility independently by
two reviewers. Reference lists of articles eligible for inclu-
sion were screened for further potentially relevant studies.
Data extraction and risk of bias assessment
Data were extracted into standardized extraction sheets
and double checked in pairs by three reviewers. These
included data on study design, risk of bias items, popu-
lation characteristics, study setting, study intervention
and results for the relevant outcomes (means and stand-
ard deviations). In studies that only reported p-values,
t-values or confidence intervals, we derived standard de-
viations from these statistics using the methods described
in Chapter 7 of the Cochrane Handbook for Systematic
Reviews [5].
Risk of bias was assessed for RCTs by random sequence
generation, allocation concealment, completeness of follow-
up and selective reporting bias. Judgements were made
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of bias tool [6].Data synthesis and analysis
Data were entered into RevMan 5 and pooled. Mean dif-
ferences (MD) and their corresponding 95% confidence
intervals (CI) were calculated for outcomes that were
measured on scales of considerable similarity. Otherwise
standardised mean differences were calculated. Meta-
analyses were conducted using random-effects models as
the underlying rationale of random-effects models may
be more appropriate when pooling heterogeneous data,
while fixed and random-effects models produce the same
result if data are homogenous. A downside of random-
effects models is that more weight is given to small studies
which may have a higher risk of bias (small study bias),
but this was not an issue in our review. Heterogeneity was
measured using Chi2-tests and the I2 statistic. If hetero-
geneity was detected, subgroup analyses were conducted
to explore reasons for heterogeneity. Subgroups were
planned a priori for age, gender, socioeconomic status,
type of illness (mild or severe), size of absolute effect and
severity of side effects. Where statistical heterogeneity
remained, but there was strong contextual homogeneity,
we opted in favour of pooling the data into meta-analyses,
because of their additional informational value and the
problems associated with narrative or pseudo-quantitative
interpretation of results [7]. However, in these cases we
did not pool results across subgroups.
Some studies had three comparison groups: two stud-
ies compared a verbal, percentage and natural frequency
presentation; one study compared a verbal, numerical
and combined verbal/numerical presentation [8]. In this
case we used data from both comparisons in our ana-
lyses and divided the number of participants in the
verbal group by two in order not to artificially inflate the
statistical power of these studies in the meta-analyses. In
two studies participants received two scenarios with dif-
ferent adverse effects. In cases where both scenarios
were relevant to the same meta-analysis, we averaged
the results across the two scenarios. The standard devia-
tions for these comparisons were recalculated to account
for statistical dependence assuming a correlation of 0.5
(sensitivity analyses with correlations of 0.1 and 0.9 pro-
duced similar results).Results
Search results
Figure 1 shows a flow diagram depicting the study selec-
tion process in accordance with the PRISMA statement
[9]. Our searches yielded 1201 potentially relevant articles.
Seven articles including ten studies remained eligible for
inclusion after applying the inclusion criteria [8,10-15].Description of studies
All studies were randomized controlled trials, many of
which used a factorial design. Some studies were reported
in more than one publication. All studies randomized
participants to short information leaflets on drugs for a
particular condition, which only differed in whether the
information on the frequency of the adverse effects of
the drug were presented verbally or numerically. One
study examined a combination of a verbal and numer-
ical description, as it is currently included in the 2009
European Commission Guideline on the readability of
package leaflets [16]. The interventions and outcomes
of the studies were very similar and mainly differed with
respect to the conditions and drugs that were used in
the scenarios as well as the frequency and the severity
of the side effects. The studies included five outcomes
of interest to our review: estimation of probabilities
(in percentages), likelihood of occurrence, satisfaction,
intention to take or continue to take the medicine and
the impact of the information on the decision. The last
four outcomes were all measured as one item on a 6-point
Likert scale. All outcomes were measured shortly after
distribution of the information leaflets, and none of the
studies had a follow-up. In many cases the participants
received information on more than one adverse effect,
resulting in a higher number of comparisons than stud-
ies for the outcome estimation of probability.
In all but one study participants were recruited from
the general population or via a cancer website and con-
fronted with a hypothetical scenario. The studies were all
conducted by two groups of authors from the UK, who
were interested in evaluating the effects of the nomencla-
ture used in drug package inserts in the European Union.
Thus, the verbal descriptors that were studied in the trials
were: very common, common, uncommon, rare and very
rare. See Additional file 2 for detailed characteristics of the
included studies with additional results from individual
studies regarding effect modifiers.
Risk of bias
Methods of sequence generation, allocation concealment
and information on incomplete outcome data were fre-
quently not reported. Thus, none of the studies was
formally rated low on all risk of bias items (Table 2).
Nevertheless we consider the overall risk of bias to be
low. For one thing, there was a large overlap in the
group of authors, suggesting that the methods used were
likely to be appropriate despite not being fully reported
in each study – especially considering that unconcealed
allocation was explicitly acknowledged in one study. For
another thing, the design of the studies was rather sim-
ple. Participants completed questionnaires immediately
after reading the information in the presence of the
researchers. Therefore, it can be assumed that missing
Figure 1 Study selection process. Flow-chart showing the study selection procedure according to PRISMA reporting guidelines.
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stated for each item in all publications.
One study used an unconcealed allocation. However, the
authors of the study argued that this was unlikely to bias
the results, because it seems unlikely that the researcher
could be able to anticipate the participants’ response to




There were 19 comparisons from 10 studies with 2145
observations for the outcome estimation of probabilities.
Table 2 Risk of bias of included studies
Study Random sequence generation Allocation concealment Incomplete outcome data Selective reporting
Berry 2002 Study 1 [10] Unclear Unclear Low Low
Berry 2002 Study 2 [10] Unclear Unclear Low Low
Berry 2003 Study 1 [11] Unclear Unclear Low Low
Berry 2003 Study 2 [11] Unclear Unclear Low Low
Berry 2004 [12] Unclear Unclear Low Low
Berry 2006 [13] Unclear Unclear Unclear Low
Knapp 2004 [14] Unclear High Unclear Low
Knapp 2009a [8] Low Low Unclear Low
Knapp 2009b Study 1 [8] Low Low Unclear Low
Knapp 2009 Study 2 [15] Low Low Unclear Low
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cies of adverse effects systematically led to an overesti-
mation of the probability of adverse effects compared
to a numerical presentation (MD for very common side
effects: −31.54 [CI: −43.32 to −19.77], p < 0.00001, I2 =
91%; MD for common side effects: −35.36 [CI: −39.92
to −30.81], p < 0.00001, I2 = 48%;%; MD for uncommon
side effects: −11.20 [−16.69 to −5.70], p < 0.0001, I2 =
30%; MD for rare side effects: −10.11 [−15.64 to −4.58],
p = 0.0003, I2 = 58%). The absolute magnitude of the over-
estimation was larger in the very common and common
subgroup than in the uncommon and rare subgroup, as it
would be expected (Figure 2). Subgroup analyses by fre-
quency did not fully explain the heterogeneity. The differ-
ences in frequencies used in the studies are likely to
contribute to this heterogeneity (see Additional file 3).
Interestingly, even participants who received a probabil-
ity estimate of the frequency of the adverse effects often
overestimated these values. Only between 9% and 50% of
the participants in the numerical groups gave a correct
probability for the adverse effects (see Additional file 3).
However, this was not always reported. Furthermore, the
variability in responses between participants was large,
which is indicated by large standard deviations and wide
ranges.
See Additional file 3 for a detailed table of the results
of the comparisons from each study by verbal descriptor
and type and frequency of adverse effect together with
the results of the significance tests as they were reported
in the primary studies.
Likelihood of occurrence
Likelihood of occurrence as measured on a Likert scale
was considered in 10 comparisons with 892 observa-
tions. Participants who received a verbal presentation of
the frequency of adverse effects thought they were more
likely to occur than those who received numerical infor-
mation (MD for very common side effects: 0.80 [CI: 0.24
to 1.37], p = 0.006, I2 = 85%; MD for common sideeffects: 1.39 [CI: 1.05 to 1.74], p < 0.00001, I2 = 0%; MD
for rare side effects: 0.90 [0.30 to 1.50], p = 0.003, I2 = not
applicable). We conducted a subgroup analysis by fre-
quency of adverse effect, but this did not fully explain the
large heterogeneity for this outcome (Figure 3). However,
the heterogeneity can mainly be attributed to one trial
[10], which showed a large difference and included
postgraduate or undergraduate students in contrast to
the other studies, which included participants from the
general public. Excluding this trial from the analysis
reduces the heterogeneity in the respective subgroup
from 85% to 39%.
One trial compared a numerical presentation with a
combined format. Splitting this trial from the others we
conducted a second, exploratory subgroup analysis on
this outcome. This suggested that the verbal presentation
may dilute the effects of a numerical presentation on this
outcome (test for subgroup difference, p = 0.003, analysis
not shown) [15].
Satisfaction
Satisfaction with the information was measured in 12
comparisons with 1228 observations. Satisfaction was
consistently higher in groups that received a numerical
description of the frequency of adverse effects compared
to a verbal description (MD: 0.48 [CI: 0.32 to 0.63],
p < 0.00001, I2 = 0%) (Figure 4).
Likelihood of taking the medicine
Data for the outcome likelihood of taking or continuing
to take the drug in the scenario was available from 5
comparisons with 780 observations. Participants who were
presented with numbers, stated that they were or would
be more likely to take or continue taking the drugs which
were suggested to them (MD for very common side ef-
fects: 1.45 [CI: 0.78 to 2.11], p < 0.0001, I2 = 68%; MD for
common side effects: 0.90 [CI: 0.61 to 1.19], p < 0.00001,
I2 = 1%; MD for rare side effects: 0.39 [0.02 to 0.76],
p = 0.04, I2 = not applicable) (Figure 5). There was a
Figure 2 Estimation of frequency. Meta-analysis on estimation of frequency of adverse effects.
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to the frequency of the adverse effect (p = 0.01). Based on
the EU nomenclature, this suggests that the larger the
frequency of the adverse effect, the less likely it is that
participants will take the drug, if they are presented
with a verbal format.
Impact of information on decision
The impact of the information on the decision to take or
continue to take the medication was measured in 7 com-
parisons with 532 observations. Verbal presentations of
adverse effects had a larger impact on the decision to
take the drugs than numerical presentations (MD: 0.52
[CI: 0.22 to 0.82], p = 0.0007, I2 = 0%) (Figure 6). There
was a significant subgroup effect for the difference
between a numerical and a combination of numerical
and verbal presentation, suggesting that the verbalpresentation may dilute the effects of a numerical
presentation on this outcome (test for subgroup dif-
ferences p = 0.02). However, this subgroup analysis is
restricted to one study and was conducted post hoc,
so the results should be interpreted with caution.
Discussion
This systematic review provides evidence that compared
to numerical information verbal descriptors commonly
used to communicate the frequencies of adverse effects
in written health information including “common”,
“uncommon” and “rare” lead to an overestimation of the
probability of adverse effects, when they are used as
previously suggested in the Guidelines of the European
Commission.
It could be argued that other verbal terms are needed
to describe frequencies. We are not aware of any studies
Figure 3 Likelihood of occurrence. Meta-analysis on perceived likelihood of occurrence.
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the 1998 European Commission’s guidelines though.
Some studies have asked patients to assign probability
values to a range of different verbal frequency terms
[17]. According to these studies, other words do not
appear to be better suited to describe frequencies than
those previously suggested by the European Commission.
For example, in one study in a general practice setting, the
terms “almost never” and “rarely” were associated with the
lowest frequencies [18]. The probabilities assigned to these
terms were still very high with 9.9% and 7.5%, respectively.
Furthermore, the standard deviations in these studies were
large, which is in line with our results and suggests a large
variance in the frequencies assigned to different terms.
This indicates that risk expressions should be tested for
understanding before being routinely used. Furthermore,
it suggests that there may be no verbal labels that are
suited to convey frequencies, particularly of rare ad-
verse effects.
Even participants who received numerical information
overestimated the risk of adverse effects. This is in line
with other findings showing that people are generally
poor at estimating risks [19]. Low numeracy in some of
the patients may also explain this finding. In the UK, for
example, one study suggested that one third of adults
above the age of 50 had limited functional health literacy[20]. Another possible explanation for this finding is that
patients may perceive their personal risk of experiencing
adverse effects to be larger than average.
People seem to be more satisfied with numerical pre-
sentations and that they would be more likely to take
the drugs or continue taking them. Participants also
stated that they would be less affected in their decisions
by numerical presentations. These outcomes were mea-
sured on a 6-point Likert scale. Converting difference
into percentages on the scale suggests changes between
7% and 24%, which can be considered to be in the small
to moderate, but important range. Most effects were also
in the small to moderate range based on Cohen’s inter-
pretation, when converting effects into standardised
mean differences. Some of the effects may be considered
relatively large, since there is a tendency for people to
avoid extreme answers on scales where extreme values
are labelled in absolute terms, as it was the case in the
studies included in this article [21].
Subgroup analyses suggested that combined verbal and
numerical formats may dilute the effects of the numerical
presentation on two outcomes, namely likelihood of oc-
currence (as measure on a Likert scale) and impact on
treatment decision. However, these results are based on a
post-hoc analysis and comparison with the combined for-
mat was restricted to a single trial with 100 participants.
Figure 4 Satisfaction with information. Meta-analysis on satisfaction with information.
Figure 5 Likelihood of (continuing) taking drug. Meta-analysis on likelihood of (continuing) taking the drug.
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Figure 6 Impact on decision. Meta-analysis on impact of information on (hypothetical) decision.
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Providers of patient information often have a broad
audience and face the problem that people have different
preferences regarding the need and use of risk estimates.
The meaning that is ascribed to such information varies
greatly. While some express a clear need for risk esti-
mates, others are confused by numbers and prefer to
make decisions based on other types of information [22].
Different preferences imply that using a combined verbal
and numerical format may be the best compromise to
suit various needs. This is also reflected in the current
European Commission Guideline on readability from
2009 as well as the current EU template for patient leaf-
lets [16,23]. Providing different information for different
groups according to their preferences would be an op-
tion, but it may be difficult to direct patients to the in-
formation that best suits their needs.
Unfortunately, data on adverse effects are often poorly
reported in trials and systematic reviews, which compli-
cates the issue [24,25]. Furthermore, there might still be a
role for verbal terms in written information, for example
for people with difficulties in understanding numbers, or
when large amounts of numbers make information too
difficult to comprehend. It is difficult to draw a clear rec-
ommendation for providers of patient information as it is
unlikely that there is a one-size-fits-all approach. This will
depend on many other factors such as the context and the
target group of the information.
Limitations of the review
Our review is based on a comprehensive search and
used rigorous methods for assessing and synthesisingthe included studies. However, it has some limitations.
We restricted our search to English and German stud-
ies. It is reported in accordance with the PRISMA state-
ment (Additional file 4). This may have introduced a
language bias. We do not consider this to be a major
weakness though, since it is questionable whether re-
sults can be generalized from one language to another
due to semantic differences.
Limitations of the included studies
Many studies were conducted with healthy volunteers
and used fictional scenarios. There were some exceptions:
one study included patients admitted to a cardiac rehabili-
tation centre and produced similar results. Three studies
of users of a patient information website partially included
women with experiences of breast cancer. While they also
produce similar results, these trials had some limitations,
too. Some of the women in these studies were already
taking the medication which was used in the scenario,
which questions the applicability to other populations.
An important caveat of all studies was that they used
convenience samples, which may lack representativeness.
Lastly, all outcomes were measured as single items. This
may be problematic for an outcome such as satisfaction,
which represents a complex construct. However, informa-
tion leaflets only differed in one sentence and the results
for this outcome were very homogenous, adding strength
to the findings.
Conclusions
Our review suggests that – whenever possible – adverse
treatment effects should be quantified numerically,
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expressions should be tested for understanding before
being routinely used.
Further studies should focus on the impact of personal
and contextual factors, including the setting, disease, nu-
meracy and educational level. Furthermore they should
use representative samples or be conducted in real life
settings and measure potentially more relevant outcomes
such as actual behavior (including decisions and medica-
tion adherence for example) and whether decisions are
in line with personal values. After all, risk communica-
tion is not an end in itself, but a means to the end of
making better decisions. On a more critical note, it is
questionable whether a difference solely in how infor-
mation on adverse effects is communicated could have
a detectable effect on behavioral outcomes. A recent
systematic review examined whether informing patients
about benefits and harms of medicines compared to
usual care has an impact on behavior at all [26]. Overall,
the results did not show a significant effect. This system-
atic review had some limitations including heteroge-
neous results and statistical imprecision and there is
some difficulty in interpreting the results. However, it
suggests that we may need to focus on more general
questions regarding the effects of provision of informa-
tion on behavioral outcomes.
A further unanswered question is how different for-
mats for describing the frequency of adverse effects are
interpreted when they are presented together with treat-
ment benefits, since these are also often overestimated
by patients [27]. Qualitative research methods may be
able to shed some light into how people come to assign
probabilities to words. On a final note, further research
should be conducted within the framework of a system-
atic review of the literature.Additional files
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